ASRT — Assertio Therapeutics Inc

Assertio Therapeutics Inc (ASRT) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Mark L. Reisenauer, based in 100 South Saunders Road, Lake Forest, IL, United States, 60045, with about 53 employees. Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Latest reported ASRT revenue for 2025-09-30 was $49.5M. Net income was $11.4M. Revenue was up 69.3% from 2025-06-30 to 2025-09-30. ASRT currently screens at market cap $151.5M.

Use this ASRT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ASRT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ASRT SEC filings page. Lician reads the product cache first so this HTML stays unique to Assertio Therapeutics Inc even when a live quote feed is slow.